Indomethacin Sodium
This sodium salt of indomethacin is the intravenous formulation used primarily in neonatal medicine to close patent ductus arteriosus, an abnormal blood vessel connection near the heart that should close after birth. Like the oral form, it inhibits prostaglandin synthesis through COX inhibition. The injectable form provides rapid systemic effects.
Moleküler Ağırlık
379,8000 g/mol
TPSA
71,40 Ų
Terapötik Alanlar
Etki Mekanizması
Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.
2D Yapı
Cite this structure
Embed this structure
SMILES
COc1ccc2c(c1)c(CC(=O)[O-])c(C)n2C(=O)c1ccc(Cl)cc1.O.O.O.[Na+]
InChI
InChI=1S/C19H16ClNO4.Na.3H2O/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12;;;;/h3-9H,10H2,1-2H3,(H,22,23);;3*1H2/q;+1;;;/p-1
Molecular Formula
C19H15ClNNaO4
HBD / HBA
- / 4
Döndürülebilir Bağlar
4
Ağır Atomlar
26
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
This sodium salt of indomethacin is the intravenous formulation used primarily in neonatal medicine to close patent ductus arteriosus, an abnormal blood vessel connection near the heart that should close after birth. Like the oral form, it inhibits prostaglandin synthesis through COX inhibition. The injectable form provides rapid systemic effects.
Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.
Yes, Indomethacin Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3989410. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 23675763. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="indomethacin-sodium"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/indomethacin-sodium/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/indomethacin-sodium/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/indomethacin-sodium/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="indomethacin-sodium"></drugfyi-drug>